J Appl Biomed 5:171-178, 2007 | DOI: 10.32725/jab.2007.023

The antimutagenic and cytoprotective effects of amifostine: the role of p53

Diana Grochová1,2, Jana ©mardová1,*
1 Department of Pathology, University Hospital, Brno, Czech Republic
2 Faculty of Science, Masaryk University, Brno, Czech Republic

Radiotherapy and chemotherapy are the basic approaches in cancer treatment, but these procedures are often associated with a number of undesirable side effects worsening the quality of life of the patient. In recent years a number of protective compounds capable of reducing or eliminating these side effects have been extensively investigated (for example: dexrazoxan, mesna, glutathion or N-acetylcystein). One of these compounds is amifostine (WR-2721), a broad-spectrum cytoprotective drug, selectively protecting normal tissues from the toxic effects of therapy, while the malignant tissues are subject to the anti-tumour effects of the treatment. In addition, several studies have revealed certain antimutagenic activities of amifostine making this agent potentially useful in the prevention of therapy-induced secondary malignancies. This article summarizes the information available on the antimutagenic and cytoprotective effects of amifostine and its effects also on the activity of the p53 tumour suppressor.

Keywords: amifostine; tumour suppressor p53; cytoprotective and antimutagenic compounds; WR-2721; WR-1065

Received: September 7, 2007; Published: July 31, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grochová D, ©mardová J. The antimutagenic and cytoprotective effects of amifostine: the role of p53. J Appl Biomed. 2007;5(4):171-178. doi: 10.32725/jab.2007.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Acosta JC, Richard C, Delgado MD, Horita M, Rizzo MG, Fernandez-Luna JL, Leon J: Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol. Cancer. Ther. 2:893-900, 2003.
    2. Andreassen CN, Grau C, Lindegaard J C: Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin. Radiat. Oncol. 13:62-72, 2003. Go to original source... Go to PubMed...
    3. Appella E, Anderson CW: Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764-2772, 2001. Go to original source... Go to PubMed...
    4. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC: Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res. 48:3634-3640, 1988.
    5. Camhi SL, Lee P, Choi AM: The oxidative stress response. New Horiz. 3:170-182, 1995. Go to PubMed...
    6. Capizzi RL: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin. Oncol. 26:3-21, 1999.
    7. Culy CR, Spencer CM: Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61:641-684, 2001. Go to original source... Go to PubMed...
    8. DeNeve WJ, Everett CK, Suminski JE, Valeriote FA: Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res. 48:6002-6005, 1988.
    9. Flaman JM, Robert V, Lenglet S, Moreau V, Iggo R, Frebourg T: Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene 16:1369-1372, 1998. Go to original source... Go to PubMed...
    10. Grdina DJ, Murley JS, Kataoka Y, Epperly W: Relationships between cytoprotection and mutation prevention by WR-1065. Mil. Med. 167:51-53, 2002a. Go to original source... Go to PubMed...
    11. Grdina DJ, Murley JS, Kataoka Y: Radioprotectants: current status and new directions. Oncology 63:2-10, 2002b. Go to original source... Go to PubMed...
    12. Hainaut P, Milner J: Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53:4469-4473, 1993.
    13. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr., Mitchell RB, Negrin R, Szatrowski TP et al.: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17:3333-3355, 1999. Go to original source... Go to PubMed...
    14. http://www.drugs.com, downloaded 28th February 2007.
    15. Kataoka Y, Murley JS, Patel R, Grdina DJ: Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines. Int. J. Radiat. Biol. 76:633-639, 2000. Go to original source... Go to PubMed...
    16. Koukourakis MI: Amifostine: is there evidence of tumour protection? Semin. Oncol. 30:18-30, 2003. Go to original source... Go to PubMed...
    17. Kramer DL, Vujcic S, Diegelman P, Alderfer J, Miller JT, Black JD, Bergeron RJ, Porter CW: Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res. 59:1278-1286, 1999. Go to PubMed...
    18. Lee E, Gerhold M, Palmer MW, Christen RD: p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. Br. J. Cancer. 88:754-759, 2003. Go to original source... Go to PubMed...
    19. Liu SC, Murley JS, Woloschak, Grdina DJ: Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 18:2457-2459, 1997. Go to original source... Go to PubMed...
    20. Mann K, Hainaut P: Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. Oncogene 24:3964-3975, 2005. Go to original source... Go to PubMed...
    21. Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G, Hainaut P: Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20:3533-3540, 2001. Go to original source... Go to PubMed...
    22. MedImmune Oncology, Inc.: Ethyol Monograph. Package Insert, Gaithersburg, MD 2005.
    23. Meier T, Issels RD: Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese hamster ovary cells. Biochem. Pharmacol. 50:489-496, 1995. Go to original source... Go to PubMed...
    24. Milner J: Flexibility: The key to p53 function? Trends Biochem. Sci. 20:49-51, 1995. Go to original source... Go to PubMed...
    25. Minet E, Michel G, Mottet D, Piret JP, Barbieux A, Raes M, Michiels C: c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp. Cell. Res. 265:114-124, 2001. Go to original source... Go to PubMed...
    26. Mitchell JL, Rupert J, Leyser A, Judd GG: Mammalian cell polyamine homeostasis is altered by the radioprotector WR1065. Biochem. J. 335:329-334, 1998. Go to original source... Go to PubMed...
    27. Murley JS, Constantinou A, Kamath NS, Grdina DJ: WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Prolif. 30:283-294, 1997. Go to original source... Go to PubMed...
    28. Murley JS, Grdina DJ: The effects of cycloheximide and WR-1065 on radiation-induced repair processes: A mechanism for chemoprevention. Carcinogenesis 16:2699-2705, 1995. Go to original source... Go to PubMed...
    29. Murley JS, Kataoka Y, Hallahan DE, Roberts JC, Grdina DJ: Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic. Biol. Med. 30:1426-1439, 2001. Go to original source... Go to PubMed...
    30. North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P: The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 19:1206-1214, 2000. Go to original source... Go to PubMed...
    31. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P: Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol. Carcinog. 33:181-188, 2002. Go to original source... Go to PubMed...
    32. Paasinen-Sohns A, Kielosto M, Kaariainen E, Eloranta T, Laine A, Janne OA, Birrer MJ, Holtta E: c-Jun activation-dependent tumourigenic transformation induced paradoxically by overexpression or block of S-adenosylmethionine decarboxylase. J. Cell. Biol. 151:801-810, 2000. Go to original source... Go to PubMed...
    33. Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK: Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther. 13:806-814, 2006. Go to original source... Go to PubMed...
    34. Pluquet O, North S, Bhoumik A, Dimas K, Ronai Z, Hainaut P: The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J. Biol. Chem. 278:11879-11887, 2003a. Go to original source... Go to PubMed...
    35. Pluquet O, North S, Richard MJ, Hainaut P: Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. Biochem. Pharmacol. 65:1129-1137, 2003b. Go to original source... Go to PubMed...
    36. Pollard KJ, Samuels ML, Crowley KA, Hansen JC, Peterson CL: Functional interaction between GCN5 and polyamines: A new role for core histone acetylation. EMBO J. 18: 5622-5633, 1999. Go to original source... Go to PubMed...
    37. Prives C, Hall PA: The p53 pathway. J. Pathol. 187:112-126, 1999. Go to original source... Go to PubMed...
    38. Provinciali M, Ciavattini A, Di Stefano G, Argentati K, Garzetti GG: In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. Life Sci. 64:1525-1532, 1999. Go to original source... Go to PubMed...
    39. Ramakrishnan N, Catravas GN: N-(2-mercaptoethyl)-1,3-propanediamine (WR-1065) protects thymocytes from programmed cell death. J. Immunol. 148:1817-1821, 1992. Go to original source... Go to PubMed...
    40. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P, Tassone P, Turco MC, Venuta S: Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors. Blood 94:4060-4066, 1999. Go to original source...
    41. Santini V, Giles FJ: The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica 84:1035-1042, 1999. Go to PubMed...
    42. Savoye C, Swenberg C, Hugot S, Sy D, Sabattier R, Charlier M, Spotheim-Maurizot M: Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int. J. Radiat. Biol. 71:193-202, 1997. Go to original source... Go to PubMed...
    43. Shaw L M, Bonner HS, Schuchter L, Schiller J, Lieberman R: Pharmacokinetics of amifostine: effects of dose and method of administration. Semin. Oncol. 26:34-36, 1999.
    44. Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD: Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J. Pharmacol. Exp. Ther. 297:1067-1073, 2001.
    45. Sherr CJ, Weber JD: The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10:94-99, 2000. Go to original source... Go to PubMed...
    46. Toledo F, Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6:909-923, 2006. Go to original source... Go to PubMed...
    47. van der Vijgh WJ, Korst AE: Amifostine (Ethyol): Pharmacokinetic and pharmacodynamic effects in vivo. Eur. J. Cancer 32:S26-S30, 1996. Go to original source... Go to PubMed...
    48. Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat. Rev. Cancer 2:594-604, 2002. Go to original source... Go to PubMed...
    49. Vousden KH: Activation of the p53 tumour suppressor protein. Biochim. Biophys. Acta 1602:47-59, 2002. Go to original source... Go to PubMed...
    50. Wadler S, Haynes H, Beitler JJ, Goldberg G, Holland JF, Hochster H, Bruckner H, Mandeli J, Smith H, Runowicz C: Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. J. Clin. Oncol. 11:1517-1522, 1993. Go to original source... Go to PubMed...
    51. Woloschak G E, Paunesku T, Chang-Liu CM, Grdina DJ: Expression of thymidine kinase messenger RNA and a related transcript is modulated by radioprotector WR1065. Cancer Res. 55:4788-4792, 1995. Go to PubMed...
    52. Yuhas JM, Storer JB: Differential chemoprotection of normal and malignant tissues. J. Natl. Cancer Inst. 42:331-335, 1969. Go to PubMed...
    53. Zhang X, Lai PP, Taylor YC: Differential radioprotection of cultured human diploid fibroblasts and fibrosarcoma cells by WR1065. Int. J. Radiat. Oncol. Biol. Phys. 24:713-719, 1992. Go to original source... Go to PubMed...

    Return to the content